Cited by 81HIV/AIDS drug development and treatmentComputational Drug Discovery MethodsHIV Research and Treatment

Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain

Open access
Cuzzucoli Crucitti, Giuliana, Métifiot, Mathieu, Pescatori, Luca, Messore, Antonella, Madia, Valentina Noemi, Pupo, Giovanni, Saccoliti, Francesco, Scipione, Luigi +9 more·2015·Journal of Medicinal Chemistry

Abstract

The development of HIV-1 dual inhibitors is a highly innovative approach aimed at reducing drug toxic side effects as well as therapeutic costs. HIV-1 integrase (IN) and reverse transcriptase-associated ribonuclease H (RNase H) are both selective targets for HIV-1 chemotherapy, and the identification of dual IN/RNase H inhibitors is an attractive strategy for new drug development. We newly synthesized pyrrolyl derivatives that exhibited good potency against IN and a moderate inhibition of the RNase H function of RT, confirming the possibility of developing dual HIV-1 IN/RNase H inhibitors and obtaining new information for the further development of more effective dual HIV-1 inhibitors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/jm501799k

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • HTPD has a ribonuclease H IC50 below micromolar, antiviral EC50 in the micromolar range, and CC50 above 100 micromolar.

    “HTPD exhibited an RNH IC50 below μM, antiviral EC50 in the μM range and CC50 above 100 μM [87].”

    From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [87]

    The Results and Discussion sections report RNase H inhibition and antiviral activity for pyrrolyl diketo acid derivatives, but do not identify HTPD or give measurements for it. The Cell-Based Assays section reports CC50 >50 μM for the compounds studied, not a CC50 >100 μM for HTPD. Searches for HTPD and the claimed values found no passage that verifies its three measurements. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cuzzucoli Crucitti, G., Métifiot, M., Pescatori, L., Messore, A., Madia, V. N., Pupo, G., Saccoliti, F., Scipione, L., Tortorella, S., Esposito, F., Corona, A., Cadeddu, M., Marchand, C., Pommier, Y., Tramontano, E., Costi, R., & Di Santo, R.
Affiliations
  • Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur-Fondazione Cenci Bolognetti, “Sapienza” Università di Roma, Rome, I-00185, Italy
  • National Institutes of Health (US)
  • Istituto Pasteur (IT)
  • University of Cagliari (IT)
Corresponding author
Costi, Roberta
Venue
Journal of Medicinal Chemistry
Published
2015-02-11
Volume
58
Issue
4
Pages
1915-1928
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W1965497780
Cited by
81
References
48
Citations by year
2026: 4 · 2025: 4 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 11 · 2020: 5 · 2019: 7 · 2018: 10 · 2017: 13 · 2016: 9 · 2015: 2
FWCI
9.34
Type
journal article
Language
en
Open access
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, other-oa)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • Iris (Roma Tre University) (submittedVersion)
Funders
  • National Cancer Institute
  • European Commission
  • Ministero dell'Istruzione, dell'Università e della Ricerca (2010W2KM5L_002)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords
HIV-1 integrase inhibitors, dual inhibitors, structure-activity relationship, antiretroviral drug development, HIV-1
MeSH terms
Dose-Response Relationship, Drug, HIV, Microbial Sensitivity Tests, Pyrroles, Structure-Activity Relationship, Virus Replication, Molecular Structure, Ribonuclease H, Protein Structure, Tertiary, Reverse Transcriptase Inhibitors, HIV Integrase, HIV Integrase Inhibitors, HIV Reverse Transcriptase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review